nach oben

Clinical Pharmacokinetics

Erschienen in:

01.08.2007 | Commentary

Considerations in Drug Handling in Renal Disease

verfasst von: Domenic A. Sica

Erschienen in: Clinical Pharmacokinetics | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Excerpt

The incidence of chronic kidney disease (CKD) is on the upswing in most industrialised countries. The protean nature of CKD-related diseases is such that wide arrays of healthcare providers are now routinely called on to assist in the management of these patients. Quite logically, this level of attention exposes CKD patients to diverse therapies, many of which are pharmacological in nature; thus, the interplay between CKD and the dosing of various drug therapies becomes an important treatment consideration that requires continuous vigilance.[1] …

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl. 1): S1–S266

Sica DA. Kinetics of angiotensin converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol 1992; 20 Suppl. 10: S13–20PubMed

Frishman WH, Alwarshetty M. β-adrenergic blockers in systemic hypertension. Clin Pharmacokinet 2002; 41: 505–16PubMedCrossRef

Brater DC. Diuretic therapy. N Engl J Med 1998; 339: 387–95PubMedCrossRef

Sica DA. Hypertension, renal disease, and drug considerations. J Clin Hypertens (Greenwich) 2004; 6: 24–30CrossRef

Vaidyanathan S, Bigler H, Yeh CM, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007; 46(8): 661–75PubMedCrossRef

US FDA Center for Drug Evaluation and Research. Guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling [online]. Rockville (MD): Center for Drug Evaluation and Research, 1998. Available from URL: http://www.fda.gov/cder/guidance/1449fnl.pdf [Accessed 2007 Jun 26]

Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 2001; 10: 785–92PubMedCrossRef

Titel: Considerations in Drug Handling in Renal Disease
verfasst von: Domenic A. Sica
Publikationsdatum: 01.08.2007
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 8/2007
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200746080-00004

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2007

Clinical Pharmacokinetics and Use of Infliximab

Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris

Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol

General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs

Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren Alone and in Combination with Irbesartan in Renal Impairment